Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Hong Kong · Delayed Price · Currency is HKD 31.38
+0.80 (2.62%)
Oct 15, 2026, 4:08 PM HKT
HKG:3692 Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 190,248 | 218,427 | 102,545 | 93,358 | 87,864 | 112,525 | |
Market Cap Growth | -14.09% | 113.00% | 9.84% | 6.25% | -21.92% | -49.44% |
Enterprise Value | 151,978 | 188,836 | 77,426 | 72,847 | 68,167 | 95,387 |
Last Close Price | 31.38 | 35.56 | 16.84 | 15.08 | 14.05 | 17.80 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 24.54 | 35.33 | 22.04 | 25.86 | 30.08 | 33.79 |
Forward PE | 24.39 | 36.29 | 24.05 | 28.31 | 24.97 | 27.09 |
PS Ratio | 10.37 | 13.06 | 7.86 | 8.39 | 8.28 | 9.23 |
PB Ratio | 4.36 | 5.55 | 3.36 | 3.29 | 3.43 | 4.58 |
P/TBV Ratio | 4.42 | 5.61 | 3.39 | 3.31 | 3.44 | 4.58 |
P/FCF Ratio | 32.72 | 30.76 | 26.47 | 29.25 | 31.49 | 43.30 |
P/OCF Ratio | 30.13 | 29.13 | 24.95 | 27.19 | 28.35 | 35.57 |
PEG Ratio | 3.18 | 4.18 | 3.63 | 3.12 | 1.56 | 1.11 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 8.28 | 11.29 | 5.93 | 6.54 | 6.43 | 7.82 |
EV/EBITDA Ratio | 20.82 | 29.44 | 17.01 | 21.86 | 20.57 | 25.20 |
EV/EBIT Ratio | 22.19 | 31.42 | 18.65 | 24.68 | 23.13 | 27.55 |
EV/FCF Ratio | 26.14 | 26.59 | 19.99 | 22.83 | 24.43 | 36.71 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.11 | 0.00 | 0.00 | 0.17 | 0.19 | 0.19 |
Debt / EBITDA Ratio | 0.67 | 0.02 | 0.03 | 1.41 | 1.48 | 1.24 |
Debt / FCF Ratio | 0.84 | 0.02 | 0.03 | 1.49 | 1.77 | 1.81 |
Net Debt / Equity Ratio | -0.88 | -0.89 | -0.81 | -0.80 | -0.76 | -0.75 |
Net Debt / EBITDA Ratio | -5.27 | -5.46 | -5.45 | -6.80 | -5.88 | -4.90 |
Net Debt / FCF Ratio | -6.58 | -4.93 | -6.40 | -7.10 | -6.99 | -7.14 |
Asset Turnover | 0.39 | 0.42 | 0.38 | 0.32 | 0.33 | 0.41 |
Inventory Turnover | 2.26 | 2.41 | 1.82 | 2.02 | 2.03 | 2.46 |
Quick Ratio | 4.78 | 7.92 | 9.90 | 4.11 | 9.64 | 7.50 |
Current Ratio | 4.88 | 8.09 | 10.18 | 4.21 | 9.86 | 7.67 |
Return on Equity (ROE) | 19.40% | 17.35% | 16.05% | 13.53% | 12.11% | 14.31% |
Return on Assets (ROA) | 9.08% | 9.44% | 7.54% | 5.31% | 5.70% | 7.35% |
Return on Invested Capital (ROIC) | 108.98% | 98.79% | 63.34% | 43.96% | 44.33% | 50.64% |
Return on Capital Employed (ROCE) | 15.60% | 15.20% | 13.50% | 10.20% | 9.50% | 11.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.05% | 2.83% | 4.54% | 3.87% | 3.32% | 2.96% |
FCF Yield | 3.06% | 3.25% | 3.78% | 3.42% | 3.18% | 2.31% |
Dividend Yield | 1.38% | 1.20% | 1.95% | 1.35% | 0.67% | 0.47% |
Payout Ratio | 30.13% | 36.22% | 42.51% | 19.90% | 27.56% | 14.04% |
Buyback Yield / Dilution | -1.96% | -0.52% | 1.16% | -1.52% | 1.14% | -2.04% |
Total Shareholder Return | -0.58% | 0.68% | 3.10% | -0.17% | 1.81% | -1.57% |